{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:00:10Z","timestamp":1770040810172,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T00:00:00Z","timestamp":1522281600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"CNPq Research Productivity, Brazil","award":["302622\/2015-2"],"award-info":[{"award-number":["302622\/2015-2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s11255-018-1854-5","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T22:33:49Z","timestamp":1522794829000},"page":"993-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Estrogen therapy in patients with prostate cancer: a contemporary systematic review"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2092-414X","authenticated-orcid":false,"given":"Leonardo Oliveira","family":"Reis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emerson Luis","family":"Zani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herney Andr\u00e9s","family":"Garc\u00eda-Perdomo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,29]]},"reference":[{"issue":"4","key":"1854_CR1","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins C, Hodges CV (1941) Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1(4):293\u2013297","journal-title":"Cancer Res"},{"issue":"4","key":"1854_CR2","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s11255-012-0134-z","volume":"44","author":"E Dias Silva","year":"2012","unstructured":"Dias Silva E, Ferreira U, Matheus W, Faria EF, Silva GD, Saito M, de Souza AA, Laranjo A Jr, Clark O, Magna LA, Castilho LN, Reis LO (2012) Goserelin versus leuprolide in the chemical castration of patients with prostate cancer. Int Urol Nephrol 44(4):1039\u20131044","journal-title":"Int Urol Nephrol"},{"issue":"20","key":"1854_CR3","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1056\/NEJM198411153112004","volume":"311","author":"The Leuprolide Study Group","year":"1984","unstructured":"The Leuprolide Study Group (1984) Leuprolide versus diethylstilbestrol for metastatic prostate cancer. The Leuprolide Study Group. N Engl J Med 311(20):1281\u20131286","journal-title":"N Engl J Med"},{"issue":"2","key":"1854_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0022-5347(05)00161-8","volume":"175","author":"ED Crawford","year":"2006","unstructured":"Crawford ED, Sartor O, Chu F, Perez R, Karlin G, Garrett JS (2006) A 12-month clinical study of LA-2585 (45.0 MG): a new 6-month subcutaneous delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 175(2):533\u2013536","journal-title":"J Urol"},{"issue":"2","key":"1854_CR5","doi-asserted-by":"publisher","first-page":"81","DOI":"10.3816\/CGC.2002.n.009","volume":"1","author":"WK Oh","year":"2005","unstructured":"Oh WK (2005) The evolving role of estrogen therapy in prostate cancer. Clin Prostate Cancer 1(2):81\u201389","journal-title":"Clin Prostate Cancer"},{"issue":"5","key":"1854_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1097\/01.ju.0000061024.75334.40","volume":"169","author":"J Ockrim","year":"2003","unstructured":"Ockrim J, Lalani E, Laniado M, Carter S, Abel P (2003) Transdermal estradiol therapy for advanced prostate cancer\u2014forward to the past? J Urol 169(5):1735\u20131737","journal-title":"J Urol"},{"issue":"13","key":"1854_CR7","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1093\/jnci\/88.13.908","volume":"88","author":"CN Robertson","year":"1996","unstructured":"Robertson CN, Roberson KM, Padilla GM, O\u2019Brien ET, Cook JM, Kim CS et al (1996) Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 88(13):908\u2013917","journal-title":"J Natl Cancer Inst"},{"key":"1854_CR8","first-page":"1","volume":"343","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD (2011) The Cochrane Collaboration\u2019 s tool for assessing risk of bias in randomised trials 343:1\u20139","journal-title":"The Cochrane Collaboration\u2019 s tool for assessing risk of bias in randomised trials"},{"issue":"4","key":"1854_CR9","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/S0022-5347(17)62926-4","volume":"98","author":"LJ Arduino","year":"1967","unstructured":"Arduino LJ, Bailar JC, Becker LE, Berman HI, Bischoff AJ, Doe RP et al (1967) Carcinoma of the prostate: treatment comparisons. J Urol 98(4):516\u2013522","journal-title":"J Urol"},{"issue":"2","key":"1854_CR10","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1002\/1097-0142(197008)26:2<257::AID-CNCR2820260203>3.0.CO;2-9","volume":"26","author":"JC Bailar","year":"1970","unstructured":"Bailar JC, Byar DP (1970) Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo. Cancer 26(2):257\u2013261","journal-title":"Cancer"},{"issue":"2","key":"1854_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/j.1464-410X.1989.tb05162.x","volume":"63","author":"P Henriksson","year":"1989","unstructured":"Henriksson P, Edhag O (1989) Patients at high risk of cardiovascular complications in oestrogen treatment of prostatic cancer. Br J Urol 63(2):186\u2013190","journal-title":"Br J Urol"},{"issue":"2","key":"1854_CR12","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/j.1464-410X.1988.tb05062.x","volume":"61","author":"F Lund","year":"1988","unstructured":"Lund F, Rasmussen F (1988) Flutamide versus stilboestrol in the management of advanced prostatic cancer: a controlled prospective study. Br J Urol 61(2):140\u2013142. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.1988.tb05062.x","journal-title":"Br J Urol"},{"issue":"8","key":"1854_CR13","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1200\/JCO.1996.14.8.2250","volume":"14","author":"A Chang","year":"1996","unstructured":"Chang A, Yeap B, Davis T, Blum R, Hahn R, Khanna O et al (1996) Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. J Clin Oncol 14(8):2250\u20132257","journal-title":"J Clin Oncol"},{"issue":"2","key":"1854_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/0090-4295(85)90042-1","volume":"26","author":"R Sharifi","year":"1985","unstructured":"Sharifi R, Lee M (1985) Comparison of leuprolide and diethylstilbestrol for stage D2 adenocarcinoma of prostate. Urology 26(2):117\u2013124","journal-title":"Urology"},{"issue":"6","key":"1854_CR15","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S0022-5347(17)50832-0","volume":"131","author":"H Winfield","year":"1984","unstructured":"Winfield H, Trachtenberg J (1984) A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer. J Urol 131(6):1107\u20131109","journal-title":"J Urol"},{"issue":"3","key":"1854_CR16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000463975","volume":"18","author":"LEF Moffat","year":"1990","unstructured":"Moffat LEF (1990) Comparison of zoladex, diethylstilbestrol and cyproterone acetate treatment in advanced prostate cancer. Eur Urol 18(3):26\u201327","journal-title":"Eur Urol"},{"issue":"6","key":"1854_CR17","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1464-410X.1992.tb15633.x","volume":"69","author":"B Waymont","year":"1992","unstructured":"Waymont B, Lynch T, Dunn J, Emtage L, Arkell D, Wallace D et al (1992) Phase III randomised study of zoladex versus stilboestrol in the treatment of advanced prostate cancer. Br J Urol 69(6):614\u2013620. \n                    https:\/\/doi.org\/10.1111\/j.1464-410X.1992.tb15633.x","journal-title":"Br J Urol"},{"key":"1854_CR18","first-page":"47","volume":"303","author":"LA Emtage","year":"1989","unstructured":"Emtage LA, Trethowan C, Kelly K, Arkell D, Wallace DM, Hughes M et al (1989) A phase III open randomized study of zoladex 3.6\u00a0mg depot vs. DES 3\u00a0mg per day in untreated advanced prostate cancer: a West Midlands Urological Research Group Study. Prog Clin Biol Res 303:47\u201352","journal-title":"Prog Clin Biol Res"},{"issue":"2","key":"1854_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1002\/pros.2990180206","volume":"18","author":"DL Citrin","year":"1991","unstructured":"Citrin DL, Resnick M (1991) A comparison of zoladex and DES in the treatment of advanced prostate cancer: results of a randomized, multicenter trial. Prostate 18(2):139\u2013146","journal-title":"Prostate"},{"issue":"3","key":"1854_CR20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000087797","volume":"75","author":"R Manikandan","year":"2005","unstructured":"Manikandan R, Srirangam SJ, Pearson E, Brown SCW, O\u2019Reilly P, Collins GN (2005) Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial. Urol Int 75(3):217\u2013221","journal-title":"Urol Int"},{"issue":"8","key":"1854_CR21","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1046\/j.1442-2042.2002.00495.x","volume":"9","author":"N Burns-Cox","year":"2005","unstructured":"Burns-Cox N, Basketter V (2005) Prospective randomised trial comparing diethylstilboestrol and flutamide in the treatment of hormone relapsed prostate cancer. Int J Urol 9(8):431\u2013434","journal-title":"Int J Urol"},{"issue":"11","key":"1854_CR22","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1002\/cncr.24283","volume":"115","author":"LG Taylor","year":"2009","unstructured":"Taylor LG, Canfield SE, Du XL (2009) Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer. Cancer 115(11):2388\u20132399","journal-title":"Cancer"},{"issue":"2","key":"1854_CR23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJMoa041943","volume":"352","author":"VB Shahinian","year":"2005","unstructured":"Shahinian VB, Kuo Y-F, Freeman JL, Goodwin JS (2005) Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 352(2):154\u2013164. \n                    https:\/\/doi.org\/10.1056\/NEJMoa041943","journal-title":"N Engl J Med"},{"issue":"2 Pt 1","key":"1854_CR24","first-page":"535","volume":"167","author":"D Scherr","year":"2005","unstructured":"Scherr D, Pitts WR, Vaughn ED (2005) Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer. J Urol 167(2 Pt 1):535\u2013538","journal-title":"J Urol"},{"issue":"2","key":"1854_CR25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF00298427","volume":"57","author":"S Eriksson","year":"1995","unstructured":"Eriksson S, Eriksson A, Stege R, Carlstrom K (1995) Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcif Tissue Int 57(2):97\u201399","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"1854_CR26","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/0090-4295(92)90401-H","volume":"40","author":"JI Miller","year":"1992","unstructured":"Miller JI, Ahmann FR (1992) Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer. Urology 40(6):499\u2013502","journal-title":"Urology"},{"issue":"5 Suppl","key":"1854_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0090-4295(89)90106-4","volume":"33","author":"WB Peeling","year":"1989","unstructured":"Peeling WB (1989) Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma. Urology 33(5 Suppl):45\u201352","journal-title":"Urology"},{"key":"1854_CR28","unstructured":"Reis LO, De Mendon\u00e7a GB, Carneiro BD, Schneider E, Gewehr EV, Meirelles A et al (2011) Diethylstilbestrol 1\u00a0mg in the treatment of acute urinary retention due to prostatic obstruction in the elderly: a preliminary study. Adv Urol 984382. \n                    http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24575128"},{"issue":"5","key":"1854_CR29","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1097\/01.ju.0000077558.48257.3d","volume":"170","author":"DS Scherr","year":"2003","unstructured":"Scherr DS, Pitts WR (2003) The nonsteroidal effects of diethylstilbestrol: the rationale for androgen deprivation therapy without estrogen deprivation in the treatment of prostate cancer. J Urol 170(5):1703\u20131708","journal-title":"J Urol"},{"issue":"1","key":"1854_CR30","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1200\/JCO.1997.15.1.382","volume":"15","author":"EJ Small","year":"1997","unstructured":"Small EJ, Vogelzang NJ (1997) Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J Clin Oncol 15(1):382\u2013388","journal-title":"J Clin Oncol"},{"key":"1854_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1111\/j.1464-410X.2012.11206.x","volume":"110","author":"P Bosset","year":"2012","unstructured":"Bosset P, Albiges L, Seisen T, De T, Rouge M, Bitker M et al (2012) Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int 110:826\u2013829","journal-title":"BJU Int"},{"issue":"6","key":"1854_CR32","doi-asserted-by":"publisher","first-page":"e97080","DOI":"10.1371\/journal.pone.0097080","volume":"9","author":"R Rosa-Ribeiro","year":"2014","unstructured":"Rosa-Ribeiro R, Nishan U, Vidal RO, Barbosa GO, Reis LO, Cesar CL et al (2014) Transcription factors involved in prostate gland adaptation to androgen deprivation. PLoS ONE 9(6):e97080. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0097080","journal-title":"PLoS ONE"},{"issue":"3","key":"1854_CR33","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1007\/s12032-011-9991-z","volume":"29","author":"LO Reis","year":"2012","unstructured":"Reis LO (2012) Old issues and new perspectives on prostate cancer hormonal therapy: the molecular substratum. Med Oncol 29(3):1948\u20131955","journal-title":"Med Oncol"},{"issue":"6","key":"1854_CR34","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.urology.2014.02.001","volume":"83","author":"KO Rove","year":"2014","unstructured":"Rove KO, Crawford ED, Perachino M, Morote J, Klotz L, Lange PH, Andriole GL, Matsumoto AM, Taneja SS, Eisenberger MA, Reis LO (2014) Maximal testosterone suppression in prostate cancer\u2013free vs total testosterone. Urology 83(6):1217\u20131222","journal-title":"Urology"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-018-1854-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-018-1854-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,28]],"date-time":"2019-03-28T20:11:25Z","timestamp":1553803885000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-018-1854-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,29]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["1854"],"URL":"https:\/\/doi.org\/10.1007\/s11255-018-1854-5","relation":{},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,29]]},"assertion":[{"value":"8 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the review reported.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}